Cingulate Equity Warrants Exp 03rd Dec 2026 CINGW:NASDAQ

RT Quote | NASDAQ | USD
Last | 01/27/23 EST
0.20UNCH (UNCH)
52 week range
0.15 - 0.55
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.20
  • 52 Week High0.55
  • 52 Week High Date03/23/22
  • 52 Week Low0.15
  • 52 Week Low Date05/25/22

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.20
  • 52 Week High0.55
  • 52 Week High Date03/23/22
  • 52 Week Low0.15
  • 52 Week Low Date05/25/22
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cingulate Equity Warrants Exp 03rd Dec 2026

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Cingulate Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The...
Shane Schaffer Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Laurie Myers Ph.D.
Chief Operating Officer, Executive Vice President
Louis Van Horn
Chief Financial Officer, Executive Vice President
Address
1901 W. 47Th Place
Kansas City, KS
66205
United States